Logo Image
News
Media
Medical World NewsPodcastsVideosInsightsPeer ExchangeMedia DayNews NetworkRoundtablesShorts
Conference
Conference CoverageConference Listing
Publication
More
CME/CE
Partners
Resources
Interactive ToolsSpecial ProjectsSponsored
Contribute
Case StudiesWriters and Mentors
Clinical Forum Insights

Subscribe

  • News
  • Media
  • Conference
  • Publication
  • CME/CE
  • Partners
  • Resources
  • Contribute
  • Subscribe
  • Clinical Forum Insights
  • Antimicrobial Stewardship
  • Blood-Borne Diseases
    • Ebola
    • HCV / Hepatitis
  • Coronavirus / COVID
  • Food Borne Infection / Food Safety
    • E. Coli
    • Food Safety
    • Listeria
    • Salmonella
  • Fungal Infections
    • Candida auris
  • Gastrointestinal Infections
    • C. Difficile
    • H. Pylori
    • Norovirus
  • Healthcare Associated Infections (HAI)
  • Prevention
    • Antibiotics
    • Immunizations
    • Vaccines
  • Respiratory Infections
    • Community-Acquired Pneumonia
    • Measles
    • Influenza
  • Sexually Transmitted Diseases
    • HIV / AIDS
    • HPV
    • HSV
    • PrEP
  • Skin & Soft Tissue Diseases
    • MRSA
  • Zoonotic & Vector-Borne Diseases
    • Lyme Disease
    • ZIKA
Spotlight -
Vaccines in America|
Antibiotics Deconstructed|
Bench to Bedside With SIDP|
Antimicrobial Stewardship|
Hepatitis
Advertisement

Jennifer Lo, PharmD

Advertisement

Articles by Jennifer Lo, PharmD

"Antibiotic Never Events": The Ideal Target to Reduce Antimicrobial Exposure

ByBradley Langford, PharmD, BCPS*,Jennifer Lo, PharmD,Kevin Schwartz, MD, MSc, FRCPC
October 15th 2019

By stopping unnecessary antibiotics before they start, clinicians can avoid unnecessary harm to the patient and the population.

Advertisement

Latest Updated Articles

  • "Antibiotic Never Events": The Ideal Target to Reduce Antimicrobial Exposure
    "Antibiotic Never Events": The Ideal Target to Reduce Antimicrobial Exposure

    October 15th 2019



Advertisement
Advertisement

Trending on Contagion Live

1

Review of Cefepime and Zidebactam: A Novel Antibiotic Approved to Treat Complicated Urinary Tract Infections

2

Bepirovirsen Phase 3 Results Offer Potential Cure for Chronic Hepatitis B

3

FDA Expands Merck Pneumococcal Vaccine Indication to Include At-Risk Children and Adolescents

4

FDA Approves Tebipenem Pivoxil as First Oral Carbapenem For Complicated Urinary Tract Infections

5

FDA Approves First Generic Version of Influenza Antiviral Baloxavir

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us